AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PHAT · NASDAQ · Biotechnology

Phathom Pharmaceuticals

Brings Takeda's vonoprazan acid blocker to U.S. patients under the VOQUEZNA brand.

$9.45

Pre-market−0.12 (−1.20%)

At close$9.57(+4.19%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	1	2	7	16	30	29	40	50	58	58	74
Cost of revenue	0	0	0	1	2	4	4	5	6	8	12	15
Gross profit	0	0	1	6	14	26	25	34	43	50	46	59
	36	70	71	83	85	85	104	94	59	56	62	63
Research & development	12	13	9	7	9	9	9	9	7	7	8	8
	23	57	62	76	76	77	94	85	52	48	54	55
General & administrative	0	0	0	76	0	0	0	0	0	0	0	0
Operating income	−36	−70	−70	−77	−71	−59	−79	−60	−15	−6	−15	−4
	−8	−10	−13	−14	−15	−15	−15	−16	−15	−15	−15	−14
Interest income	3	3	4	4	4	4	3	2	1	1	2	2
Interest expense	10	13	17	18	18	19	18	18	16	16	16	15
Other non-operating income	−3	−3	−4	−4	−4	−4	−3	−2	−1	−1	−1	−1
Income before tax	−43	−80	−83	−91	−86	−74	−94	−76	−30	−21	−30	−18
Net income from continuing operations	−43	−80	−83	−91	−86	−74	−94	−76	−30	−21	−30	−18
Net income	−43	−80	−83	−91	−86	−74	−94	−76	−30	−21	−30	−18
EPS, basic	−$0.76	−$1.39	−$1.42	−$1.56	−$1.32	−$1.05	−$1.31	−$1.05	−$0.41	−$0.29	−$0.37	−$0.21
EPS, diluted	−$0.76	−$1.39	−$1.42	−$1.56	−$1.32	−$1.05	−$1.31	−$1.05	−$0.41	−$0.29	−$0.37	−$0.21
Weighted average shares, basic	57	57	58	59	65	71	72	72	73	74	82	84
Weighted average shares, diluted	57	57	58	59	65	71	72	72	73	74	82	84
EBITDA	−33	−66	−65	−73	−67	−56	−76	−58	−14	−5	−14	−2
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−33	−67	−66	−74	−67	−56	−76	−58	−14	−5	−15	−2